Vasopressin Polymer Excipient Composition for Long-Term Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of vasopressin suffer from poor long-term stability, leading to significant degradation and reduced efficacy over time.
Innovation Solution
A pharmaceutical composition comprising vasopressin and a polymeric pharmaceutically-acceptable excipient, which stabilizes vasopressin by reducing degradation by up to 10% over a week at 60°C compared to formulations without the excipient.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If vasopressin is formulated with traditional excipients, then the formulation is simple to manufacture, but the long-term stability is poor and degradation is significant
Solution Approach 1:
The patent uses a composite excipient system combining polyethylene glycol (PEG) 4000 or PEG 6000 with polysorbate 80 in specific ratios (e.g., 9:1 to 1:9). This composite approach provides synergistic stabilization effects where PEG forms a protective hydration shell around vasopressin molecules while polysorbate 80 prevents aggregation and maintains solubility, achieving superior long-term stability compared to traditional single excipients
Solution Approach 2:
The patent optimizes specific parameters including the PEG molecular weight (4000 or 6000), the PEG to polysorbate 80 ratio, and the concentration ranges (PEG: 0.1-10% w/v, polysorbate 80: 0.01-1% w/v). These parameter adjustments create an optimal stabilization environment that reduces degradation by maintaining proper hydration and preventing molecular aggregation over extended storage periods
2Duration of action of stationary object
If vasopressin is stored at room temperature, then the storage conditions are convenient, but the degradation rate is high and shelf life is limited
Solution Approach 1:
The patent incorporates PEG and polysorbate 80 as pre-formulated stabilizers that create a protective environment around vasopressin molecules before storage begins. This protective matrix cushions against thermal stress and chemical degradation pathways, allowing the formulation to maintain stability at room temperature (20-25°C) for at least 24 months without requiring refrigeration
Solution Approach 2:
PEG acts as an intermediary substance between vasopressin and the aqueous environment, modulating water activity and preventing direct interactions that lead to degradation. The PEG-polysorbate 80 complex mediates the physical-chemical environment, creating a buffered system that protects the peptide from pH shifts, oxidation, and hydrolysis during long-term storage
3Stability of the object's composition
If the concentration of polymeric excipient is increased, then the stability improvement is greater, but the formulation complexity and manufacturing difficulty increase
Solution Approach 1:
The patent employs moderate concentrations of PEG (0.1-10% w/v) and polysorbate 80 (0.01-1% w/v) rather than extreme amounts. This partial action approach achieves sufficient stabilization (reducing degradation while avoiding the formation of precipitates, foam, or viscosity issues that would complicate manufacturing and quality control
Solution Approach 2:
The patent specifies optimal concentration ranges and ratios that balance stabilization efficacy with manufacturability. By defining PEG at 0.1-10% and polysorbate 80 at 0.01-1%, the formulation achieves adequate protection against degradation while remaining compatible with standard pharmaceutical manufacturing processes, filtration, and sterilization protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition extends the shelf life of vasopressin formulations to at least 30 months at room temperature and significantly reduces degradation, maintaining therapeutic effectiveness.
Implementation Method 1
a polymeric pharmaceutically-acceptable excipient, which stabilizes vasopressin by reducing degradation by up to 10% over a week at 60°C compared to formulations without the excipient
Data Source
AI summary
Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.